Skip to main content
Clinical Trials/DRKS00028147
DRKS00028147
Not yet recruiting
Phase 1

Effects of single and multiple oxygen administration under elevated ambient pressure on the healthy human kidney - RENOX

HBO-Zentrum Euregio Aachen0 sites20 target enrollmentFebruary 16, 2022
ConditionsTINNITUS

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
TINNITUS
Sponsor
HBO-Zentrum Euregio Aachen
Enrollment
20
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
HBO-Zentrum Euregio Aachen

Eligibility Criteria

Inclusion Criteria

  • HBO therapy in the context of a hearing loss/ tinnitus
  • \- No known previous kidney diseases
  • \- No known vascular diseases
  • \- GFR \> 90m/min (via CKD\-EPI)
  • \- No use of permanent medication with influence on renal function
  • \- Sufficient knowledge of German

Exclusion Criteria

  • \- GFR \< 90ml/min
  • \- Diseases with limitation of endocrine and exocrine renal function
  • \- Known intolerance to high ambient pressures with inability to equalize pressure (via Valsalva maneuver). Exclusion is based on patient history and symptoms.
  • \- Diseases of the middle ear
  • \- claustrophobia
  • \- Pulmonary disorders, such as severe bronchial asthma, emphysema, pneumothorax, acute infectious diseases
  • \- Acute upper respiratory tract and/or sinus infections with sinunasal congestion (stuffy nose or rhinitis)
  • \- Non\-removable implants such as pacemakers, drug pumps, breast implants depending on manufacturer's instructions
  • \- Pregnancy and lactation
  • \- Severe cardiovascular diseases, in particular uncontrolled or poorly controlled arterial hypertension or heart failure

Outcomes

Primary Outcomes

Not specified

Similar Trials